About Event
The 6th Cytokine-Based Drug Development Summit brought together 70+ CxOs, VPs, Directors, and Scientists who collaborated and connected to help deliver life-changing therapies to patients.
The 6th Cytokine-Based Drug Development Summit returned as the only industry-focused conference that provided practical knowledge, reflective lessons, and innovative approaches to overcome challenges in cytokine drug development. The Summit offered a unique opportunity for the exchange of information and networking in this field - all geared toward assisting with the successful progression of candidates into and through the clinic.
With a focus on the immunoregulatory role that cytokine-based drugs played in disease, attendees explored how engineered cytokine drugs and novel approaches could widen the therapeutic window and maximize the translation of cytokine-associated toxicities. Preclinical experts examined the challenges related to interleukins (IL-2, IL-6, IL-10, IL-12, IL-18), interferons, cytokine mimetics, and toxicities such as cytokine release syndrome (CRS).
Participants gained exclusive insights into the latest advancements in understanding and applying preclinical models, as well as the biology and potential role of synthetic cytokines and cytokine-based drugs in the treatment of oncology and inflammatory diseases.
Who Was In the Room?
Conference Highlights Included:
Discover effective approaches to overcome key toxicity challenges in cytokine-based therapies, such as their short half-lives and high receptor affinity. Learn about innovative strategies and immune system modulation to reduce toxicity and enhance safety profiles, with insights from Sanofi and Sonnet Biotherapeutics as we shift our focus to Immunology and Inflammation as well as Oncology
Dive into novel masking techniques employed by industry leaders like Candel Therapeutics, Regeneron, OSE Immunotherapeutics, and Werewolf Therapeutics to improve specificity, boost delivery, and minimize toxicity in cytokine therapies
Explore the challenges of using animal models in cytokine-based therapies. Assess the limitations of current models and discover how ModeX and Synthekine are advancing the field to improve translational relevance, enhancing the likelihood of clinical success
Gain insight into the global factors contributing to clinical failures in cytokine-based therapies. By understanding the root causes of these setbacks and leveraging emerging trends, you’ll be better positioned to identify promising research areas and maximize the potential for successful cytokine therapies, with guidance from Beacon
